21 CFR § 203.12 - An appeal from an adverse decision by the district office.
---
identifier: "/us/cfr/t21/s203.12"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 203.12 - An appeal from an adverse decision by the district office."
title_number: 21
title_name: "Food and Drugs"
section_number: "203.12"
section_name: "An appeal from an adverse decision by the district office."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "C"
subchapter_name: "DRUGS: GENERAL"
part_number: "203"
part_name: "PRESCRIPTION DRUG MARKETING"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 331, 333, 351, 352, 353, 360, 371, 374, 381."
regulatory_source: "64 FR 67756, Dec. 3, 1999, unless otherwise noted."
cfr_part: "203"
---
# 203.12 An appeal from an adverse decision by the district office.
An appeal from an adverse decision by the district office involving insulin-containing drugs or human prescription drugs or biological products regulated by the Center for Drug Evaluation and Research may be made to the Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. An appeal from an adverse decision by the district office involving human prescription biological products regulated by the Center for Biologics Evaluation and Research may be made to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002.
[80 FR 18090, Apr. 3, 2015]